323 related articles for article (PubMed ID: 33451350)
1. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
Rodgers F; Pepperrell T; Keestra S; Pilkington V
Trials; 2021 Jan; 22(1):59. PubMed ID: 33451350
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Jones CW; Woodford AL; Platts-Mills TF
BMJ Open; 2020 Sep; 10(9):e041276. PubMed ID: 32948577
[TBL] [Abstract][Full Text] [Related]
4. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
7. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
8. Possible treatment and strategies for COVID-19: review and assessment.
Trivedi N; Verma A; Kumar D
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12593-12608. PubMed ID: 33336780
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of COVID-19 drugs in a real clinical setting.
Chiu MN; Bhardwaj M; Sah SP
Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
[TBL] [Abstract][Full Text] [Related]
11. One year update on the COVID-19 pandemic: Where are we now?
Mishra SK; Tripathi T
Acta Trop; 2021 Feb; 214():105778. PubMed ID: 33253656
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
13. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
[TBL] [Abstract][Full Text] [Related]
14. Treatment of SARS-CoV-2: How far have we reached?
Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
[TBL] [Abstract][Full Text] [Related]
15. Can we use hydroxychloroquine to treat COVID-19 now?
Chen J; Liu D; Yin L; Zhang L; Lu H
Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
[No Abstract] [Full Text] [Related]
16. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
[TBL] [Abstract][Full Text] [Related]
17. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
Paul SS; Biswas G
Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of drugs for COVID-19: a systematic review and meta-analysis.
Kotecha P; Light A; Checcucci E; Amparore D; Fiori C; Porpiglia F; Dasgupta P; Elhage O
Panminerva Med; 2022 Mar; 64(1):96-114. PubMed ID: 33073552
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Raj CTD; Kandaswamy DK; Danduga RCSR; Rajasabapathy R; James RA
Arch Microbiol; 2021 Jul; 203(5):2043-2057. PubMed ID: 33555378
[TBL] [Abstract][Full Text] [Related]
20. Impact of repurposed drugs on the symptomatic COVID-19 patients.
Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
